Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome
about
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settingsDeprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping reviewClinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinicThe effectiveness of anticonvulsants in psychiatric disordersTreatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatmentBAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders.Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.Modulation of ion channels in clinical psychopharmacology: adults and younger people.Risk versus risk: a review of benzodiazepine reduction in older adults.A Review of Alprazolam Use, Misuse, and Withdrawal.Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series.Oxcarbazepine in rapid benzodiazepine detoxification.Efficacy and tolerability of trazodone retard monotherapy: results of the Serbian non-interventional study.Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation.Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study.
P2860
Q24245399-B10E36DA-77B4-40AC-B3E6-6CE8AC5A68D0Q26826838-07E095B6-C3A2-4C74-9C1C-43D2AA3C58A8Q28262343-042C0ACF-CED4-4171-87FD-4A2B95D97C69Q28744504-9730506B-E919-4710-83A2-C18D8B0B98BCQ33263687-1D5BBCDF-6643-4E2C-804B-5AA9B8F7DDB4Q34277168-20903BA5-260D-45F1-9AFF-8016BD62BEFBQ35939596-A826A5B4-4910-417D-A7FE-E933A2BE3C1EQ37141499-7538B773-1A0C-4797-8436-B09F02559ED2Q37960095-7323E50F-5EE1-44AE-B134-7D77FA666978Q38218200-AC3B7DCC-2FA4-49ED-A261-759FC49F73C7Q38641123-430E1F16-CDC0-45E5-90C2-361E1C916065Q43118938-CE6B5656-2D18-4BD1-AA84-B16034829BC5Q46343528-859CE584-C927-41B6-93BC-0A3B743ACC54Q47996390-2C25E46F-78B2-4EF0-B00B-EEA0C33201D9Q51937580-81C87E5A-ADE3-4444-A993-5FF560A0C97BQ53827427-7A9266AF-0A6B-4139-9F99-67E2D6FBBE51Q55080624-1428BCC6-69D6-47C4-A22A-2E712EE40E1F
P2860
Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@ast
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@en
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@nl
type
label
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@ast
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@en
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@nl
prefLabel
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@ast
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@en
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@nl
P2093
P356
P1433
P1476
Trazodone and valproate in pat ...... wal symptoms and taper outcome
@en
P2093
D Greenblatt
E Schweizer
F Garcia España
N DeMartinis
P2888
P356
10.1007/S002130050798
P407
P577
1999-01-01T00:00:00Z
P6179
1006987393